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1. Clinical trials have demonstrated the potential of ex vivo hematopoietic stem cell gene therapy to
treat severe combined immunodeficiencies (SCID-X1 and ADA-SCID) using gammaretroviral
vectors.
Cavazzana-Calvo et al., Science 2000;288(5466):669-72
Gaspar et al., Lancet 2004;364(9452):2181-7
Aiuti et al., NEJM, 2009;360(5):447-58
 
2. The clinical benefit of gene therapy using gammaretoriviral vectors has been tempered by the 
occurrence of leukemia in 5 SCID-X1 patients in the SCID-X1 trials.
Hacein-Bey-Abina et al., J Clinical Investigation 2008;118(9):3132-42
Howe, et al., J Clinical Investigation 2008;118(9):3143-5
 
3. Integration of retroviral vectors took place preferentially in gene coding regions and was skewed
towards the transcriptional start site of highly expressed genes.
Deichmann et al., J Clinical Investigation 2007;117(8):2225-32
 
4.  Integration analysis in pre-clinical evaluation in animal models reveals the relative safety potential 
of new gene therapy vectors under investigation, allowing those vectors with potentially
dangerous integration patterns to be excluded before use in human patients and adding a further
argument in favor of vectors with a low risk of triggering insertional mutagenesis.
This thesis
 
5. The importance of pre-transplant conditioning for consistent successful correction by stem cell 
gene therapy should have an impact on current clinical protocol development.
This thesis
 
6. X-linked agammaglobulinaemia patients sometimes have significant levels of serum 
immunoglobulins, but nevertheless suffer from recurrent infections.
Timmers et al., Clinical Immunology and Immunopathology 1991;61(2):S83-93
 
7. Reprogramming of primary human fibroblasts into pluripotent stem cells is possible using only
factors OCT4 and SOX2 in the presence of histone deacetylase inhibitor valproic acid.
Huangfu et al., Nature Biotechnology 2008;26:1269-75
 
8. The human thymus contains multipotent CD34+ progenitor cells that are able to develop into
lymphoid, myeloid and erythroid lineages, but lack sufficient self-renewal capacity to be
considered true hematopoietic stem cells.
Weerkamp et al, Blood 2006;107(8):3131-3137
 
9. Since 2008, the costs of DNA sequencing have been decreasing at a rate far faster than the
corresponding increase in the number of transistors per integrated circuit over the same time 
period.
National Human Genome Research Institute
 
10. Due to time dilation, a 33-year old human travelling at 0.9c could celebrate his 40thth birthday
orbiting Barnard’s Star while back on Earth his mother simultaneously celebrates his 48th.
 
11. Never turn your back on a drug.
Hunter S. Thompson, Fear and Loathing in Las Vegas, 1971
